Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
86 results about "Cyclic dinucleotides" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cyclic-Dinucleotides and Its Conjugates as Adjuvants and Their Uses in Pharmaceutical Compositions
ActiveUS20080286296A1Severe formLess immunomodulatory effectOrganic active ingredientsAntipyreticDiseaseAutoimmune responses
The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and / or immunomodulators for prophylactic and / or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.
Owner:GESELLSCHAFT FUR BIOTECHNOLOGISCHE FORSCHUNG MBH GBF
Method for stimulating the immune, inflammatory or neuroprotective response
Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant. Cyclic di-GMP, or a cyclic dinucleotide analogue thereof, also has neuroprotective properties for use as a neuroprotective agent to inhibit, treat, or ameliorate the effects of injuries, diseases,
Owner:KARAGEN PHARMA INC +1
Compositions and methods for inhibiting "stimulator of interferon gene" -dependent signalling
ActiveUS20140341976A1Suppress overreactionOrganic active ingredientsSugar derivativesPurineStimulator of interferon genes
The present invention provides cyclic-di-nucleotide (CDN) compounds that inhibit signaling at a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides which inhibit STING-dependent TBK1 activation and the resulting production of type I interferon.
Owner:ADURO BIOTECH
Method for stimulating the immune, inflammatory or neuroprotective response
Owner:KARAGEN PHARMA INC
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
Owner:ADURO BIOTECH
Method for stimulating the immune, inflammatory or neuroprotective response
Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant. Cyclic di-GMP, or a cyclic dinucleotide analogue thereof, also has neuroprotective properties for use as a neuroprotective agent to inhibit, treat, or ameliorate the effects of injuries, diseases, disorders or conditions that result in neurodegeneration.
Owner:KARAGEN PHARMA INC
Method for stimulating the immune, inflammatory or neuroprotective response
ActiveUS20070281897A1Stimulating and enhancing immune and responseStimulating and enhancing and inflammatory responseBiocideGenetic material ingredientsAdjuvantCyclic di-GMP
Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant. Cyclic di-GMP, or a cyclic dinucleotide analogue thereof, also has neuroprotective properties for use as a neuroprotective agent to inhibit, treat, or ameliorate the effects of injuries, diseases,
Owner:KARAGEN PHARMA INC +1
Cyclic dinucleotides for cytokine induction
ActiveUS20160362441A1Improve the immunityDelay EliminationAntibacterial agentsOrganic active ingredientsPurineIn vivo
A cyclic dinucleotide compound of Formula (I):wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.
Owner:KAYLA THERAPEUTICS
Method For Attentuating Virulence Of Microbial Pathogens And For Inhibiting Microbial Biofilm Formation
ActiveUS20070244059A1Reduced virulenceInhibiting and reducing colonizationAntibacterial agentsBiocideMicroorganismVirulent characteristics
The present invention relates to the use of the cyclic dinucleotide c-di-GMP and cyclic dinucleotide analogues thereof in a method for attenuating virulence of a microbial pathogen or for inhibiting or reducing colonization by a microbial pathogen. This method further inhibits microbial biofilm formation and is capable of treating bacterial infections. The microbial colonization or biofilm formation inhibited or reduced may be on the skin or on nasal or mucosal surface. The microbial colonization or biofilm formation inhibited can also be on the surfaces of medical devices, especially those in close contact with the patient, as well on the surfaces of industrial and construction material where microbial colonization and biofilm formation is of concern.
Owner:KARAOLIS DAVID K R
Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
ActiveUS20160074507A1Enhance immune responseInactivation/attenuationVertebrate cellsVirus-like particlePyrimidine Nucleotides
The present invention relates to methods for preparing virus-like particles comprising immunogenic cyclic dinucleotides.
Owner:INSTITUT CURIE +1
Cyclic dinucleotides for cytokine induction
ActiveUS10011630B2High activityImprove bioavailabilityAntibacterial agentsOrganic active ingredientsPurineIn vivo
A cyclic dinucleotide compound of Formula (I):wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.
Owner:KAYLA THERAPEUTICS
Method for attentuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
Owner:KARAOLIS DAVID K R
Vaccine composition
ActiveUS20130266612A1Efficient inductionSsRNA viruses negative-senseBacterial antigen ingredientsMucosal Immune ResponsesWhole body
An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2 / 6 (TLR2 / 6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.
Owner:NITTO DENKO CORP
Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
ActiveUS20050203051A1Inhibit cancer cell proliferationIncreasing cancer cell apoptosisBiocideSenses disorderCyclic di-GMPIn vivo
Owner:KARAGEN PHARMA INC
Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
ActiveUS20160287698A1Antibacterial agentsOrganic active ingredientsPyrimidine NucleotidesPharmacology
Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.
Owner:BROCK UNIVERSITY +1
Cyclic dinucleotides as sting agonists
Owner:JANSSEN BIOTECH INC
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
The present disclosure relates to 2′3′ cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.
Owner:INST OF ORGANIC CHEM & BIOCHEMISTRY OF THE ACAD OF SCI OF THE CZECH REPUBLIC
Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.
Owner:BROCK UNIVERSITY +1
Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
InactiveUS20180369268A1Suppress overreactionReduced activityOrganic active ingredientsOrganic chemistryDiseaseNucleotide
The present invention relates to the use cyclic-di-nucleotide and related scaffold molecules that measurably inhibit STING signaling, and methods for their use in identifying more potent inhibitors of STING signaling. In particular, the methods provided can be used to identify potent inhibitors of STING signaling, which are useful in the treatment of autoimmune and inflammatory diseases. Also provided are compounds having STING inhibitory activity useful in the treatment of autoimmune and inflammatory diseases.
Owner:ADURO BIOTECH
Vaccine composition for mucosal administration
InactiveUS20140234377A1Improve complianceImprove immunityPeptide/protein ingredientsGenetic material ingredientsImmuno modulationPyrimidine Nucleotides
The present invention provides a vaccine composition which comprises a cellular immunity induction promoter universally usable against various antigens in cellular immunity induction by mucosal administration of the antigen and exerts a high cellular immunity inducing effect by mucosal administration. The present invention provides a vaccine composition for mucosal administration to induce cellular immunity, comprising: (i) an antigen; and (ii) one or more cellular immunity induction promoters selected from the group consisting of a TLR ligand, a cyclic dinucleotide, a helper peptide and an immunomodulatory small molecule drug.
Owner:NITTO DENKO CORP
Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
InactiveUS20170340658A1Good treatment effectEffective treatmentOrganic active ingredientsAntineoplastic agentsCombined useAgonist
A kit of parts includes a) gemcitabine or a pharmaceutically acceptable salt thereof and b) a cyclic dinucleotide or pharmaceutically acceptable salt thereof, wherein the cyclic dinucleotide or pharmaceutically acceptable salt thereof is an agonist of the receptor known as “stimulator of interferon genes” (STING), for use in the treatment of solid pancreatic cancer.
Owner:INVIVOGEN
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
Provided herein are the 3′3′ cyclic phosphonate dinucleotides of general formula J, their pharmaceutically acceptable salts, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.
Owner:USTAV ORGANICKE CHEM A BIOCHEMIE AV CR V V I
Vaccine composition
ActiveUS9498527B2Efficient inductionSsRNA viruses negative-senseBacterial antigen ingredientsMucosal Immune ResponsesWhole body
An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2 / 6 (TLR2 / 6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.
Owner:NITTO DENKO CORP
2'2' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
Provided herein are 2′2′ cyclic phosphonate dinucleotides of formula (J), their pharmaceutically acceptable salts, hydrates or solvates, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, the dinucleotides can be used as adjuvants in vaccines.
Owner:INST OF ORGANIC CHEM & BIOCHEMISTRY OF THE ACAD OF SCI OF THE CZECH REPUBLIC
Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
ActiveUS11001605B2Good membrane permeabilityImprove biological activityOrganic active ingredientsSugar derivativesMembrane permeabilizationNucleotide
Cyclic dinucleotides are described, which in contrast to their natural congeners carry lipophilic nucleobases and have higher membrane permeability and increased biological activity.
Owner:BIOLOG LSI FORSCHUNGS & BET GMBH
Cyclic di-nucleotide compounds and methods of use
ActiveUS10519188B2Improve efficacyImprove stabilityOrganic active ingredientsSugar derivativesNucleotidePharmaceutical Substances
Owner:IMMUNESENSOR THERAPEUTICS INC +1
Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
InactiveUS20190328762A1Organic active ingredientsSugar derivativesStimulator of interferon genesAgonist
Therapeutic combinations that comprise at least one antagonist of the Programmed Death 1 receptor (PD-1) and at least one cyclic dinucleotide compound that activates the Stimulator of Interferon Genes (STING) pathway are disclosed herein. Also disclosed is the use of such therapeutic combinations for the treatment of cancers.
Owner:MERCK SHARP & DOHME CORP
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
InactiveUS20190359645A1Organic active ingredientsSugar derivativesPyrimidine NucleotidesBiochemistry
The present disclosure relates to 2′3′-cyclic dinucleotides comprising a carbocyclic nucleotide and derivatives thereof, that can modulate the activity of the STING adaptor protein.
Owner:INST OF ORGANIC CHEM & BIOCHEM V V I
Cyclic dinucleotide analogues, pharmaceutical composition of analogues and applications of analogues and pharmaceutical composition
The invention discloses cyclic dinucleotide analogues, a pharmaceutical composition of the analogues and applications of the analogues and the pharmaceutical composition. The cyclic dinucleotide analogs (I), an isomer, prodrug, stable isotope derivative or pharmaceutically acceptable salt of the analogs have a structure shown in the specification. The cyclic dinucleotide analogs provided by the invention can be used as regulators of stimulator of interferon genes (STIG) and related signaling pathways, and can effectively treat and / or alleviate multiple types of diseases, including but not limited to malignant tumors, inflammation, autoimmune diseases and infectious diseases; and in addition, the STING regulators can also be used as vaccine adjuvants.
Owner:SHANGHAI DE NOVO PHARMA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com